Julia Bradbury is detailing how her 2021 breast cancer diagnosis saved her life. The Irish-born BBC television presenter — ...

AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...

Find insight on AstraZeneca, Fresenius, ConvaTec, and more in the latest Market Talks covering the Health Care sector.

Interim data has shown benefits of the camizestrant combo over standard treatment in ESR1-mutant breast cancer.

Astrazeneca shares rose nearly 1% following unexpectedly positive interim results from a Phase III trial of its breast cancer drug Camizestrant. The study revealed that patients with hormone ...

AstraZeneca (AZN) shared positive interim data from the ongoing SERENA-6 Phase 3 trail evaluating camizestrant and CDK4/6 inhibitors as a ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ: AZN) stands against the other ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...